Copeland K C
Department of Pediatrics, University of Vermont College of Medicine, Burlington 05405.
J Clin Endocrinol Metab. 1988 Jun;66(6):1278-82. doi: 10.1210/jcem-66-6-1278.
Previously reported data with regard to the effects of estrogen on plasma somatomedin-C (Sm-C) concentrations are contradictory. This study was designed to evaluate, in the same subjects with Turner's syndrome, the effects of both acute high dose and chronic low dose estrogen treatment on plasma Sm-C concentrations. Eight girls with Turner's syndrome, aged 10 8/12 to 14 9/12 yr, were admitted to the Clinical Research Center for 3 days. Each received an iv infusion of conjugated estrogens (1.25 or 2.5 mg) in 12 h. Plasma Sm-C and serum GH and estrone levels were measured before, during, and after the infusion. The mean serum concentrations in the girls who received 1.25 mg conjugated estrogen increased from less than 222 pmol/L to 1905 +/- 240 (+/- SE), 825 +/- 166, and 296 +/- 74 pmol/L immediately after, 12 h after, and 24 h after completion of the infusion, respectively. Serum GH concentrations were undetectable (less than 1 microgram/L) before, during, and after the infusion. The mean plasma Sm-C concentrations decreased significantly (P = 0.02) after the infusion was terminated, falling from a mean basal value of 1.3 +/- 0.2 (+/- SE) to a nadir of 0.6 +/- 0.1 U/mL 12 h after completion of the infusion. The same girls then were treated with low dose (5 micrograms ethinyl estradiol) estrogen therapy for 9-14 months. Seven of the eight girls had an increase in growth rate. The mean growth rate increased from 2.0 +/- 0.5 to 5.4 +/- 0.8 and 3.8 +/- 0.4 cm/yr from 3 to 6 (P less than 0.05) and from 9 to 14 months of treatment, respectively. Individual variability was great, however, and two of the eight girls never grew at a rate faster than 4.0 cm/yr during therapy. No consistent alteration in bone age relative to chronological age was found, and the growth response was not predicted by the bone age at the beginning of treatment. Mean plasma Sm-C concentrations did not change. These studies demonstrated a growth spurt in girls with Turner's syndrome during chronic low dose estrogen therapy, which was not associated with any change in plasma Sm-C concentrations. Acute high dose iv estrogen infusion resulted in a significant decline in plasma Sm-C concentrations. These results support the concept that in girls with Turner's syndrome the plasma Sm-C response to estrogen is influenced by multiple, as yet undefined, factors.
先前报道的有关雌激素对血浆生长调节素C(Sm-C)浓度影响的数据相互矛盾。本研究旨在评估在患有特纳综合征的同一组受试者中,急性大剂量和慢性小剂量雌激素治疗对血浆Sm-C浓度的影响。八名年龄在10又8/12至14又9/12岁的特纳综合征女孩被收入临床研究中心3天。每人在12小时内接受静脉输注结合雌激素(1.25或2.5毫克)。在输注前、输注期间和输注后测量血浆Sm-C、血清生长激素(GH)和雌酮水平。接受1.25毫克结合雌激素的女孩,其血清平均浓度在输注结束后立即、12小时后和24小时后分别从低于222皮摩尔/升升至1905±240(±标准误)、825±166和296±74皮摩尔/升。输注前、输注期间和输注后血清GH浓度均未检测到(低于1微克/升)。输注终止后,血浆Sm-C平均浓度显著下降(P = 0.02),从平均基础值1.3±0.2(±标准误)降至输注结束后12小时的最低点0.6±0.1 U/mL。然后,同样这些女孩接受低剂量(5微克乙炔雌二醇)雌激素治疗9至14个月。八名女孩中有七名生长速率增加。平均生长速率分别从治疗3至6个月时的2.0±0.5厘米/年增加到5.4±0.8厘米/年(P<0.05),以及从治疗9至14个月时的3.8±0.4厘米/年。然而,个体差异很大,八名女孩中有两名在治疗期间生长速率从未超过4.0厘米/年。未发现骨龄相对于实际年龄有一致的改变,并且治疗开始时的骨龄无法预测生长反应。血浆Sm-C平均浓度没有变化。这些研究表明,患有特纳综合征的女孩在慢性低剂量雌激素治疗期间出现生长加速,这与血浆Sm-C浓度的任何变化均无关。急性大剂量静脉输注雌激素导致血浆Sm-C浓度显著下降。这些结果支持这样一种概念,即在患有特纳综合征的女孩中,血浆Sm-C对雌激素的反应受多种尚未明确的因素影响。